Role of postmastectomy radiation therapy after neoadjuvant chemotherapy in locally advanced breast cancer

dc.contributor.authorAkyürek, S.
dc.contributor.authorYavaş, G.
dc.date.accessioned2020-03-26T18:48:17Z
dc.date.available2020-03-26T18:48:17Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractNeoadjuvant chemotherapy for primary breast cancer is the gold standard in the treatment of locally advanced, inoperable breast cancer, and also based on a large body of evidence has become a standard treatment option for patients with operable disease, who are clear candidates for adjuvant chemotherapy. There are several advantages of administering neoadjuvant chemotherapy: tumor downstaging, improving the chance of breast conserving surgery, in vivo assessment of tumor sensitivity to the chosen therapeutic regimen, and early control of micro-metastatic disease. However there are substantially less data to aid in determining which patients treated with neo-adjuvant chemotherapy warrant postmastectomy radiotherapy. According to the recent literature, patients who require mastectomy after systemic therapy should receive postmastectomy radiotherapy. Copyright © Experimental Oncology, 2013.en_US
dc.identifier.endpage271en_US
dc.identifier.issn1812-9269en_US
dc.identifier.issue4en_US
dc.identifier.pmid24382436en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage267en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30191
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofExperimental Oncologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectBreast canceren_US
dc.subjectLocally advanceden_US
dc.subjectNeoadjuvant chemotherapyen_US
dc.subjectRadiotherapyen_US
dc.titleRole of postmastectomy radiation therapy after neoadjuvant chemotherapy in locally advanced breast canceren_US
dc.typeReviewen_US

Dosyalar